| High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults | Journal of Clinical Oncology | 2017 | 227 |
| Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis | Nature Communications | 2017 | 104 |
| Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy | Journal of the American Society of Nephrology: JASN | 2017 | 69 |
| Intravascular imaging in coronary artery disease | Lancet, The | 2017 | 64 |
| Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study | Oral Diseases | 2017 | 60 |
| Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results | Blood | 2017 | 45 |
| Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT | Annals of Oncology | 2017 | 43 |
| Renal and Systemic Effects of Calorie Restriction in Patients With Type 2 Diabetes With Abdominal Obesity: A Randomized Controlled Trial | Diabetes | 2017 | 43 |
| Use of Everolimus in Liver Transplantation: Recommendations From a Working Group | Transplantation | 2017 | 39 |
| Temporal electronic phenotyping by mining careflows of breast cancer patients | Journal of Biomedical Informatics | 2017 | 35 |
| Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients | British Journal of Cancer | 2017 | 34 |
| Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations | Leukemia | 2017 | 33 |
| Safety and Tolerability of Neladenoson Bialanate, a Novel Oral Partial Adenosine A1 Receptor Agonist, in Patients With Chronic Heart Failure | Journal of Clinical Pharmacology | 2017 | 33 |
| Validation of the acute leukemia-EBMT score for prediction of mortality following allogeneic stem cell transplantation in a multi-center GITMO cohort | American Journal of Hematology | 2017 | 23 |
| European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia | American Journal of Hematology | 2017 | 23 |
| Mutation spectrum of NF1 gene in Italian patients with neurofibromatosis type 1 using Ion Torrent PGM™ platform | European Journal of Medical Genetics | 2017 | 23 |
| Outcomes of patients with atypical haemolytic uraemic syndrome with native and transplanted kidneys treated with eculizumab: a pooled post hoc analysis | Transplant International | 2017 | 22 |
| Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration. | Journal of Clinical Oncology | 2017 | 21 |
| Association of the HLA-B*53:01 Allele With Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome During Treatment of HIV Infection With Raltegravir | Clinical Infectious Diseases | 2017 | 20 |
| Should we treat congenital heart block with fluorinated corticosteroids? | Autoimmunity Reviews | 2017 | 20 |
| Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter? | Future Oncology | 2017 | 19 |
| Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: a retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO) | Bone Marrow Transplantation | 2017 | 16 |
| Early and Late Factors Impacting Patient and Graft Outcome in Pediatric Liver Transplantation: Summary of an ESPGHAN Monothematic Conference | Journal of Pediatric Gastroenterology and Nutrition | 2017 | 16 |
| Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration. | Journal of Clinical Oncology | 2017 | 16 |
| Efficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting: a multicenter study | Oncotarget | 2017 | 15 |
